Citalopram-Induced Long QT Syndrome and the Mammalian Dive Reflex by unknown
CASE REPORT
Citalopram-Induced Long QT Syndrome and the Mammalian
Dive Reflex
Frank F. Vincenzi1,2 • Philippe Lunetta3,4
Published online: 1 August 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract While SCUBA diving, a 44-year-old Caucasian
patient had an abnormal cardiac rhythm, presumably Tor-
sade de Pointes (TdP), during the initial descent to depth.
Upon surfacing, she developed ventricular fibrillation and
died. The patient had been treated for mild depression for
nearly a year with citalopram 60 mg per day, a drug known
to cause prolonged QT interval. She had also been treated
with two potentially hepatotoxic drugs. Liver impairment
causes selective loss of cytochrome P450 (CYP) 2C19
activity, the major pathway for metabolism of citalopram.
The post mortem blood level of citalopram was 1300 ng/
mL. The patient was found to be an intermediate metabo-
lizer via CYP2D6, the major pathway for metabolism of
desmethylcitalopram; the level of which was also abnor-
mally high. It is suggested that drug-induced long QT
syndrome (DILQTS), caused by citalopram, combined with
the mammalian dive reflex triggered malignant ventricular
rhythms resulting in the patient’s death. It is further sug-
gested that, in general, the dive reflex increases the risk of
fatal cardiac rhythms when the QT interval is prolonged by
drugs.
Key Points
Long-term high dosage and impaired metabolism
apparently accounted for accumulation of high, but
presumably non-lethal levels, of citalopram and
desmethylcitalopram in a 44-year-old woman who
died while SCUBA diving.
Prolongation of the QT interval, a well-known effect
of citalopram, increases the risk of fatal cardiac
rhythms; a risk that is further increased by
bradyarrhythmias.
It is suggested that citalopram-induced long QT
coupled with the mammalian dive reflex resulted in a
fatal cardiac rhythm in this case.
Introduction
In August 2011, the US FDA issued a Drug Alert con-
cerning citalopram (Celexa). The alert indicated that
citalopram should not be used at doses greater than 40 mg
per day because it causes dose-dependent QT interval
prolongation. The maximum recommended dose was
20 mg per day for patients with hepatic impairment, age
greater than 60 years, cytochrome P450 (CYP) 2C19 poor
metabolizers, or patients taking concomitant CYP2C19
inhibitors, such as cimetidine. It was further noted that
citalopram should not be used in patients with congenital
long QT syndrome (LQTS). Electrocardiographic moni-
toring was recommended if citalopram is used in patients
with congestive heart failure, bradyarrhythmias, predispo-
sition to hypokalemia or hypomagnesemia, or in combi-
nation with other QT-prolonging drugs.
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Citalopram
The 44-year-old patient, who was a non-smoker and rarely
consumed small amounts of alcohol, had taken citalopram
40 mg per day for mild depression since before July 2009.
At that time, she was also taking bupropion (Wellbutrin)
200 mg per day. Likewise, since before July 2009 she had
taken nadolol 40 mg/day for mild hypertension that was
well controlled. In July 2009 she was prescribed divalproex
(Depakote extended release [ER]) 250 mg/day, the
dosage of which was increased to 500 mg per day in 2010
and increased again to 1000 mg per day in January 2011.
At that time, she was also taking meloxicam (Mobic)
15 mg per day. The latter two medications were given for
frequent migraine headaches. In January 2011, bupropion
was discontinued when the dosage of citalopram was
increased from 40 to 60 mg per day.
On 5 May 2011, aspartate aminotransferase (AST) was
146 (range 6–35 U/L) and alkaline phosphatase (ALK
PHOS) was 118 (range 30–125 U/L). Repeat testing on 8
May 2011 found AST at 75, ALK PHOS at 210, and ala-
nine transaminase (ALT) at 172 (range 8–40 U/L). At that
time, the meloxicam dosage was discontinued. However,
divalproex was continued at 1000 mg per day and citalo-
pram at 60 mg per day. No further liver function tests were
performed, and no electrocardiogram testing or therapeutic
drug monitoring was performed in 2011.
The patient was a certified SCUBA diver, although she
had not been diving for over a year when, in December
2011, she arranged to dive in a tropical location while on a
family vacation. While diving with a small group of
SCUBA divers led by a qualified guide, the patient ‘‘de-
veloped problems’’ during the initial descent to a depth of
about 40 feet. The guide immediately took her to the sur-
face and she was placed on the deck of the nearest dive
boat—a boat equipped with an automatic defibrillator.
Although no permanent recording exists, the patient’s
rhythm changed from apparent Torsade de Pointes (TdP)
to ventricular fibrillation, and defibrillation was not
successful.
Autopsy performed the next day by the local medical
examiner revealed an obese (body mass index [BMI]*36)
Caucasian body with pulmonary congestion and edema,
hepatic congestion, splenic congestion, and cardiomegaly.
The heart was mildly hypertrophic (420 g) and dilated.
Microscopic examination revealed interstitial myocardial
fibrosis and cardiomyocyte hypertrophy as well as an iso-
lated liver granuloma. The post mortem blood concentra-
tion of citalopram was reported at 1300 ng/mL, well above
the therapeutic level [1]. In addition, analysis of post
mortem blood resulted in the following findings: ethanol
35 mg/dL, ibuprofen 10 mcg/mL, and caffeine positive but
not quantified. While a high level of caffeine might have
contributed to the fatal outcome, it seems unlikely since
caffeine is routinely ‘positive’ in the blood of those who
consume beverages containing caffeine. In view of the
‘‘slightly enlarged heart’’ and level of citalopram, and in
the absence of other relevant findings, the medical exam-
iner concluded that the cause of death was a fatal cardiac
arrhythmia. For ease of comparison, the blood levels of
citalopram reported by various authors are expressed as ng/
mL or ng/mg.
The ratio of plasma to whole blood concentration of
citalopram is 0.74 ± 0.04 [2]. Thus, the blood concentra-
tion of 1300 ng/mL is equivalent to a plasma level of
approximately 962 ng/mL. Citalopram therapeutic and
comatose-fatal plasma concentrations are reported to be
5–110 and 5000–6000 ng/mL, respectively [1]. Thus,
although the level of citalopram in the patient’s post
mortem blood was substantially above the therapeutic
range, it was not an obvious cause of death, per se.
A number of questions arose in this case. Why was the
post mortem level of citalopram so high? It was much
higher than would be predicted if the patient had normal
metabolism of citalopram, even at the dosage of 60 mg per
day. Furthermore, why did the patient die only after
approximately 11 months of such high dosage?
One possible explanation for a high level of citalopram
and death might be an acute overdose; possibly suicidal.
However, there is no evidence that the patient was suicidal,
and family members were confident that she was happily
enjoying a vacation. Also inconsistent with acute overdose
is the fact that additional toxicology analysis in a different
laboratory resulted in a blood level of citalopram of
1426 ng/mL and a level of desmethylcitalopram of 846 ng/
mL. In patients chronically taking citalopram, the levels are
typically three to four times higher than the metabolite,
desmethylcitalopram [3]. In acute overdose, the ratio of the
parent drug to metabolite would be higher. In this patient,
the ratio of parent drug to metabolite was lower than
expected and is inconsistent with acute overdose. Com-
pared with citalopram, the relatively high level of the
metabolite that is normally eliminated mainly by CYP2D6
supported the speculation that the deceased might have
been a poor metabolizer via 2D6. Subsequent testing of
post mortem blood indicated that, genotypically, she was
an intermediate metabolizer via 2D6. In any event, acute
overdose, suicidal or accidental, was not the cause of the
high level of citalopram and its metabolite in this patient at
the time of her death.
Metabolism of citalopram to desmethylcitalopram is
carried out mainly by CYP2C19. In turn, the metabolism
of desmethylcitalopram to didesmethylcitalopram is car-
ried out mainly by CYP2D6 [3]. While about 7 % of
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Caucasians are poor metabolizers via 2D6, only about 3 %
are poor metabolizers via 2C19 [4]. The probability that a
person would be a poor metabolizer via both pathways is
very low, although such cases have been reported [4–6].
The patient in this case was found to be a genotypically
normal metabolizer via CYP2C19 and an intermediate
metabolizer via CYP2D6. The question thus arose regard-
ing the post mortem blood level of citalopram of approx-
imately 1300–1400 ng/mL. How did the level get so high,
and was citalopram the cause of the patient’s death?
Post mortem redistribution did not account for the high
level of citalopram in the patient’s blood. Because the
autopsy was performed the morning after death, there was
little time for redistribution. While some antidepressants
show substantial post mortem increases in blood concen-
tration, citalopram increased by only 25 %, even after
6.4 days post mortem [7]. Many drugs are inhibitors of one
or more CYP isoforms, but such classical drug interactions
were not apparent in this case. On the other hand, low
activity of CYP2C19 and/or CYP2D6 (especially and) as
caused by a poorly functioning liver, would promote the
accumulation of citalopram and desmethylcitalopram to
higher than expected levels [8, 9].
Irrespective of her genetic background, it is apparent
that the patient in this case became a poor metabolizer
phenotypically via both 2C19 and 2D6. The latter was
genetically determined in part and possibly worsened by
liver damage. The former was a consequence of liver
damage. Drug-induced damage to the liver by meloxicam
and by divalproex is likely. Both drugs have warnings
regarding liver dysfunction; the latter with a prominent
black box warning. Meloxicam was discontinued when the
patient’s liver enzymes were found to be elevated in May
of 2011. Divalproex, the dose of which had been increased
from 500 mg per day to 1000 mg per day in January of
2011, was continued to the time of her death. At autopsy,
her liver did not show gross anatomical defects, but
impaired function of CYP enzymes would not be apparent.
Mild to moderate liver disease is associated with a 77 %
decrease in the clearance of mephenytoin (CYP2C19) [8,
10]. Essentially, all CYP enzymes are inhibited in later
stages of liver disease [9], with a 28 % decrease in the
clearance of dapsone (CYP3A4) and a 4 % decrease in
clearance of debrisoquine (CYP2D6) [8]. The fact that mild
to moderate liver disease selectively and profoundly inhi-
bits CYP2C19, but barely inhibits CYP2D6, is nevertheless
consistent with the relatively high level of desmethylci-
talopram found in post mortem blood because the patient
inherited intermediate metabolism via CYP2D6. As noted
above, no liver function or tests were carried out after May
2011, and no determination of citalopram levels was ever
performed. Although we cannot rule out other explana-
tions, based on the scant but abnormal liver function tests
in May 2011, as well the continued application of dival-
proex, we suggest that impaired metabolism caused
accumulation of citalopram in this patient. No electrocar-
diogram was performed during 2011; thus, we are also
uncertain of the extent of QT prolongation caused by the
high level of citalopram.
Even in the absence of measured levels of the drug, it is
evident that impaired metabolism of citalopram and its
metabolite were present in this patient. Most likely, accu-
mulation of citalopram to such a high level occurred slowly
during 2011. The post mortem blood level of 1300 ng/mL
(equivalent to a plasma level of 962 ng/mL [2] was thus
about nine times the upper limit of the therapeutic plasma
level range (5–110 ng/mL) but less than that usually
associated with death (5000–6000 ng/mL) [1].
In cases in which citalopram was judged to be the
cause of death, concentrations ranged from 2000 to
6200 ng/mg whole blood [11]. The specific density of
blood is approximately 1.04 at 25 C; thus, concentrations
expressed as ng/mg are comparable to mg/L [12]. Toxic
concentrations of citalopram in autopsy cases (most were
accidental death) ranged from 400 to 900 ng/mg whole
blood. In living individuals (mostly traffic violations)
citalopram concentrations ranged from 0.0 to 300 ng/mg
[11]. The blood alcohol in these samples ranged from 0.0
to 3.1 mg/g (*310 mg/dL). Some individuals were alive
with supratherapeutic concentrations of citalopram and, in
many cases, very high levels of alcohol [11]. Therefore,
alcohol does not necessarily increase citalopram mortality
and moderately supratherapeutic concentrations of
citalopram do not increase alcohol mortality. However,
the authors speculated that ‘‘lower concentrations [of
citalopram] may cause death if combined with the intake
of high concentrations of alcohol.’’ The low level of
alcohol (35 mg/dL) in the post mortem blood of the
patient in this case may or may not have contributed to
the outcome.
In 13 cases examined forensically, citalopram was not
judged to be the underlying cause of death, but only an
‘‘incidental’’ finding. The authors concluded, ‘‘there is a
large apparent therapeutic index with postmortem con-
centrations in blood possibly ranging as least as high as
1300 ng/mL compared to its therapeutic concentration of
approximately 200 ng/mL’’ [13]. Some other individuals
survived levels of citalopram ranging from 90 to 1640 ng/
mL in post mortem blood only to die of what were judged
to be other causes [14]. These observations may help
explain how, in the case reported here, the patient survived
for nearly a year as citalopram accumulated in her body to
a concentration that was between therapeutic and a more
patently fatal concentration. They also raise the questions
of the effect of citalopram on the QT interval and why she
died while SCUBA diving.
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Drug-Induced Long QT Syndrome
Citalopram, like a number of drugs listed on CredibleMeds
(http://www.crediblemeds.org), is known to cause pro-
longed QT. The official labeling for Celexa (citalopram)
includes the following:
‘‘Citalopram causes dose-dependent QTc prolonga-
tion, an ECG abnormality that has been associated
with Torsade de Pointes (TdP), ventricular tachycar-
dia, and sudden death, all of which have been
observed in postmarketing reports for citalopram.’’
The risk of a fatal outcome as a consequence of drug-
induced long QT syndrome (DILQTS) and TdP is sub-
stantial [15, 16]. QTc is linearly dependent on the predicted
citalopram plasma concentration, with a slope of 40 ms per
mg per liter of citalopram—with a between-subject coeffi-
cient of variation of 70 % [17]. If that average value were
applied in this case, then the predicted increase in QTc
would be 38 ms. Wide inter-individual variability precludes
precise prediction and the RR interval has a large effect on
QT that would be additive to the effects of citalopram in this
case. It is unlikely that the low concentration of alcohol in
this patient contributed to QT prolongation that is observed
with moderate and high levels of alcohol [18, 19].
Unterecker et al. [20] found a close relationship between
the QTc and serum level as citalopram was eliminated from
the body following an acute overdosage [20]. At the initial
serum level of 1200 ng/mL, equivalent to 1620 ng/L blood
level [2], the QTc was approximately 540 ms. When the
drug was finally eliminated, the QTc was 430 ms [20]. At a
blood level of 1300 ng/mL, as in the case described here, the
best fit curve predicts a QTc (Bazett) of about 497 ms [20].
Individuals with genetically determined LQTS are par-
ticularly at risk for further increases in the QT interval
when the dive reflex is initiated. Facial immersion in water
causes greater increases in QT interval in children with
non-familial LQTS [21], and nearly 30 % of swimming-
related drowning cases that were referred to Tester et al.
[22] for genetic analysis carried a cardiac channel muta-
tion. Many such drownings occur in LQTS children
because their risk of a fatal cardiac arrhythmia is signifi-
cantly increased when the dive reflex is elicited. Cate-
cholaminergic polymorphic ventricular tachycardia
(CPVT), a condition that mimics LQTS in some ways, is
also associated with drowning or near drowning [23].
The Mammalian Dive Reflex
The mammalian dive reflex involves concurrent sympa-
thetic and parasympathetic activation [24] and parasym-
pathetically mediated bradycardia [25]. In addition, the
‘cold shock response’ involves sympathetically mediated
tachycardia [25]. Various conduction abnormalities, with
individual differences, are observed when a subject’s face
is immersed in water [26]. Whether this is due to one or
both of these reflexes may be uncertain. What seems
patently clear is that ‘autonomic conflict’ and abnormal
cardiac rhythms may arise when parasympathetic and
sympathetic divisions of the nervous system innervating
the heart are simultaneously activated. The FDA warning
concerning citalopram and prolonged QT specifically
mentions bradyarrhythmias. The bradycardia and auto-
nomic conflict associated with SCUBA diving is a potential
trigger for sudden death in a person with a prolonged QT
interval. Other contributing factors may have included
hypoxia caused by breath holding while equilibrating to
depth. In the case described here, DILQTS caused by a
high level of citalopram, which in turn was related to
excessive dosage and poor metabolism, may have set the
patient up for a fatal cardiac arrhythmia while diving.
Drug-Induced Long QT Syndrome and Drowning
In light of the occurrence of sudden death (i.e., fatal cardiac
rhythm) in water of individuals with inherited LQTS [22],
it seems reasonable to suggest that, in general, DILQTS is
an independent risk factor for apparent drowning. It is well
known that alcohol is the drug most commonly associated
with drowning [27, 28]. What is not commonly appreciated
is that moderate levels of alcohol induce prolonged QT and
increased QT dispersion [18, 19]. These changes increase
the risk of malignant ventricular rhythms. The question
arises whether alcohol-associated drowning in any partic-
ular case is due to psychomotor impairment and/or to a
fatal cardiac arrhythmia. Increased risk of drowning as
caused by DILQTS needs further investigation. Prelimi-
nary data, to be published separately, suggest an associa-
tion of citalopram with drowning. The case reported here is
an example of a fatal outcome when prolonged QT interval
was combined with the autonomic conflict of the mam-
malian dive reflex.
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